

Financial Disclosures

The COSTEM 2019 Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of COSTEM 2019 participants. In doing so, the COSTEM 2019 Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

Educational Content Development

The COSTEM 2019 Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Presenters

The COSTEM 2019 Congress considers financial relationships to create actual conflicts of interest when Presenters or their immediate family (defined as spouse, domestic partner, parent, child or spouse of child, or sibling or spouse of sibling of the Presenter) have both a financial relationship with a commercial interest and the opportunity to affect the policy of the COSTEM 2019 Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the COSTEM 2019 Congress of CME based on the CME providers of the Congress.

All COSTEM 2019 Faculty presenting CME are required to disclose to the activity audience the following information prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The COSTEM 2019 Congress defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

NOTE: All presenters are required to report financial disclosures, using the codes below. An individual's financial disclosures for the COSTEM 2019 Congress are listed in this Section.

COSTEM 2017 Financial Disclosure Codes

Category	Code	Description
None	N	No financial relationships
Consultant	C	Consultant fee, paid advisory boards Advisor fees for attending a meeting (for the past 1 year)
Employee	E	Employed by a commercial entity
Lecture fees	L	Lecture fees (honoraria), travel fees or reimbursements when speaking at the invitation of a commercial entity (for the past 1 year)
Equity owner	O	Equity ownership/stock options or publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or providers of commercial ophthalmic services
Patents / Royalty	P	Patents and/or royalties that might be viewed as creating a potential conflict of interest
Grant support	S	Grant support for the past 1 year (all sources) and all sources Used for this project if this form is an update for a specific talk or publication with no time limitation

Disclosure Information

Financial interest disclosures from program members and others in a position for control content
(as of October 16, 2019)

Miguel Abboud, Lebanon

N

Tobias Alexander, Germany

N

Francis Ayuk, Germany

N

Andrea Bacigalupo, Italy

Adienne

L

MSD

L

Pfizer

L

Sanofi Genzyme

L

Therakos

L

Peter Bader, Germany

Amgen

C

Jazz

C

Medac

S, C, P

Miltenyi Biotec

C

Neovii

S, C

Novartis

C, L

Riemser

S, C

Renato Bassan, Italy

Amgen

C

Inctye

C

Tamir Ben-Hur, Israel

Kadimastem

C

MAPI Pharma

C

Regenera Pharma

C

Sipnose

C

Michael R. Bishop, USA

Agios

L

Celgene

C, L

Crispr Therapeutic

C

Juno

S, C

Kite

S, C

Novartis

S, C

Pharmacyclics

L

Sanofi Genzyme

L

Catherine M. Bollard, USA

Collectis

C

Mona Therapeutics

E, O

Neximmune

O

Torque Therapeutics

O

Francesca Bonifazi, Italy

Jazz Pharma

L

Merck

L

Neovii

L

Novartis

L

Pfizer

L

Luca Castagna, France

N

Michele Cavo, Italy

Amgen

C, L

BMS

C

Celgene

C, L

Janssen

C, L

Novartis

C

Takeda

C, L

Fabio Ciceri, Italy

MolMed

C

Stefan Ciurea, USA

Cytosin

L, O

Kiadis

L

Miltenyi Biotec

S

MolMed

L

Selim Corbacioglu, Germany

N

Jan Cornelissen, Netherlands

N

Charles Craddock, UK

Abbvie

S, L

Celgene

S, L

Jazz

L

Francesco D'Amore, Denmark

N

Marcos de Lima, USA

N

Carlo Dufour, Italy

Novartis

L

Ulrich Dührsen, Germany

Abbvie

C

Alexion

C

Amgen

S, C

Celgene

S, C

Gilead

C

Janssen

C

Novartis

C

Roche

S, C

Teva

C

Hermann Einsele, Germany

Amgen

S, C

BMS

S, C

Celgene

S, C

Janssen

S, C

Novartis

S, C

Takeda

C

Jürgen Finke, Germany

Medac

S

Neovii

S, L

Riemser

S, L

Sergio A. Giralt, USA

Actinuum

S, C

Amgen

S, C

Celgene

S, C

Kite

C

J&J

S, C

Jazz Pharma

C

Miltenyi Biotec

S

Novartis

C

Spectrum Pharma

C

Takeda

S, C

Bertram Glass, Germany

N

Éliane Gluckman, France

N

Nicola Gökbüget, Germany

Amgen

S, L

Gilead

L

Kite

L

Novartis

S, L

Pfizer

S, L

Hartmut Goldschmidt, Germany

Adaptive Bio

C

Amgen

S, C

ArtTempi

L

BMS

S, C, L

Celgene

S, C, L

Chugai

S, L

Janssen

S, C, L

Munipharma

S

Novartis

S, L

Sanofi Genzyme

S, C

Takeda

S, C

Hildegard Greinix, Austria

Abbvie

L

Celgene

L

Janssen

L

Novartis

L

Therakos

L

Michael Heuser, Germany

Amgen

S

Bayer

S, C

BergenBio

S

Daichii Sankyo

S

Karyopharm

S

Novartis

S, C

Pfizer

S, C

Dieter Hoelzer, Germany

N

Ernst Holler , Germany		Jazz Pharma	S, C	Stephen Robinson , UK	
Jazz Pharma	L	Novartis	C	N	
Maat Pharma	C	Roche	S	Vanderson Rocha , France	
Neovii	S, L	Sanofi Genzyme	S, C, L	N	
Novartis	C	Takeda	C, L	Annalisa Ruggeri , France	
Sanofi Genzyme	L	Philippe Moreau , France		N	
Takeda	C	N		Wael Saber , USA	
He Huang , China		Arnon Nagler , Israel		N	
N		N		Johannes Schetelig , Germany	
Christopher Kanakry , USA		Jakob Passweg , Switzerland		N	
N		N		Norbert Schmitz , Germany	
Hans-Jochem Kolb , Germany		Steven Pavletic , USA		Celgene	O
N		N		Janssen	C
Nicolaus Kröger , Germany		Régis Peffault de Latour , France		Kite/Gilead	C
N		Alexion	S, C	Riemser	C
Arjan Lankester , Netherlands		Novartis	S, C	Stephen J. Schuster , USA	
Neovii	S	Pfizer	S, C	Abbvie	S, L
Per Ljungman , Sweden		Olaf Penack , Germany		Acerta	S, L
AiCuris	C	Astellas	L	Astra Zeneka	L
MSD	S, C	BioRad	S	Celgene	S, L
Shire/Takeda	C	Gilead	S, C, L	Dava Oncology	L
Peihua Lu , China		Jazz Pharma	S, C, L	DTRM Bio	S
N		MSD	C, L	Juno	L
Leonido Luznik , USA		Neovii	S, L	Genentech	S
N		Pfizer	L	I3Health	L
David Marks , UK		Pierre Fabre	S	Incyte	S
Novartis	C, L	Omeros	C	LoxoOncology	L
Pfizer	C, L	Sanofi Genzyme	S	Merck	S
Sarah Markt , Italy		SOBI	C	Novartis	S, L, P
N		Takeda	S	Nordi Nanovector	L
Philip L. McCarthy , USA		Alessandro Rambaldi , Italy		OncoLive	L
bluebio bio	C, L	Amgen	L	PER Oncology	L
BMS	C, L	Celgene	C	Pfizer	L
Celgene	S, C, L	Novartis	C	Portola	S
Fate Therapeutics	C, L	Pierre Fabre	L	TG Therapeutics	S
Janssen	C, L	Roche	L	Bart Lee Scott , USA	
Juno	C, L	Teva	L	Alexion	C, L
Karyopharm	C, L	Katy Rezvani , USA		Celgene	S, C
Magenta	C, L	Adicet Bio	C	Incyte	S, L
Sanofi Genzyme	C, L	Affimed	S	Jazz Pharma	L
Takeda	C, L	EMD Serono	S, C	Avichai Shimoni , Israel	
Jeffrey Miller , USA		Pharmacyclics	S	N	
CytoSen	C	Onkimmune	C	John Snowden , UK	
Dr. Reddy's Lab	C	Antonio Risitano , Italy		Actelion	L
Fate Therapeutics	S, C	Alexion	S, C, L	Gilead	L
GT BioPharma	S, C	Alnylam	S	Janssen	L
Onkimmune	C	Apellis	L	Jazz Pharma	L
Mohamad Mohty , France		Jazz	L	Mallinckrodt	L
Amgen	C	Novartis	S, C, L	Sanofi Genzyme	L
BMS	C	Pfizer	L	<i>Other: IDMC member for trial, Kiadis</i>	
Celgene	C	Raphamra	S	Robert J. Soiffer , USA	
Daiichi Sankyo	C	Roche	L	Astellas	C
Janssen	C, L	Marie Robin , France		Gilead	C
		N		Merck	C

Matthias Stelljes, Germany		Janssen	C	Robert Zeiser, Germany	
Amgen	C	MSD	C	Incyte	C
Medac	L	Roche	C	Jazz Pharma	C
MSD	C, L	Novartis	C	Novartis	C
Pfizer	S, C, L	Sanofi Genzyme	C		
		Takeda	C, L		
Rainer Storb, USA		Marcel van den Brink, USA			
N		Amgen	L		
		Evelo	L		
Jan Styczynski, Poland		Jazz Pharma	L		
Angelini	C	Magenta	L		
Astellas	L	Merck & Co., Ltd	L		
Biotest	C	Seres Therapeutics	S, L, O		
Gilead	C, L	Smart Immune	O		
Jazz Pharma	L	Therakos	L		
MSD	C, L	Daniel Weisdorf, USA			
Novartis	C	Fate Therapeutics	L		
Roche	L	Incyte	S		
Teva	L	Pharmacyclics	L		
Anna Sureda, Spain		Ibrahim Yakoub-Agha, France			
BMS	C	N			
Celgene	C				
Gilead	C				